Abstract
Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.
Original language | English |
---|---|
Pages (from-to) | 25-33 |
Number of pages | 9 |
Journal | Cancer Letters |
Volume | 350 |
Issue number | 1-2 |
DOIs | |
Publication status | Published - Aug 1 2014 |
Keywords
- Anti-cancer
- Low molecular weight heparin
- Non-anticoagulant heparin
- Pancreatic cancer
- Tumor suppressor
- Tumor survival
ASJC Scopus subject areas
- Oncology
- Cancer Research